Non-germline genetically engineered mouse models for translational cancer research

Joerg Heyer, Lawrence Kwong, Scott W. Lowe, Lynda Chin

Research output: Contribution to journalReview article

99 Citations (Scopus)

Abstract

Genetically engineered mouse models (GEMMs) of cancer have affected virtually all areas of cancer research. However, the accelerated discovery of new cancer genes emerging from large-scale cancer genomics and new chemical entities pouring from the drug discovery pipeline have strained the capacity of traditional germline mouse models to provide crucial insights. This Review introduces new approaches to modelling cancer, with emphasis on a growing collection of non-germline GEMMs (nGEMMs). These offer flexibility, speed and uniformity at reduced costs, thus paving the way for much needed throughput and practical preclinical therapeutic testing models.

Original languageEnglish (US)
Pages (from-to)470-480
Number of pages11
JournalNature Reviews Cancer
Volume10
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Translational Medical Research
Neoplasms
Neoplasm Genes
Drug Discovery
Genomics
Costs and Cost Analysis
Research
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Non-germline genetically engineered mouse models for translational cancer research. / Heyer, Joerg; Kwong, Lawrence; Lowe, Scott W.; Chin, Lynda.

In: Nature Reviews Cancer, Vol. 10, No. 7, 01.07.2010, p. 470-480.

Research output: Contribution to journalReview article

Heyer, Joerg ; Kwong, Lawrence ; Lowe, Scott W. ; Chin, Lynda. / Non-germline genetically engineered mouse models for translational cancer research. In: Nature Reviews Cancer. 2010 ; Vol. 10, No. 7. pp. 470-480.
@article{3de24e42954848d6a5f930f282cd2736,
title = "Non-germline genetically engineered mouse models for translational cancer research",
abstract = "Genetically engineered mouse models (GEMMs) of cancer have affected virtually all areas of cancer research. However, the accelerated discovery of new cancer genes emerging from large-scale cancer genomics and new chemical entities pouring from the drug discovery pipeline have strained the capacity of traditional germline mouse models to provide crucial insights. This Review introduces new approaches to modelling cancer, with emphasis on a growing collection of non-germline GEMMs (nGEMMs). These offer flexibility, speed and uniformity at reduced costs, thus paving the way for much needed throughput and practical preclinical therapeutic testing models.",
author = "Joerg Heyer and Lawrence Kwong and Lowe, {Scott W.} and Lynda Chin",
year = "2010",
month = "7",
day = "1",
doi = "10.1038/nrc2877",
language = "English (US)",
volume = "10",
pages = "470--480",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Non-germline genetically engineered mouse models for translational cancer research

AU - Heyer, Joerg

AU - Kwong, Lawrence

AU - Lowe, Scott W.

AU - Chin, Lynda

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Genetically engineered mouse models (GEMMs) of cancer have affected virtually all areas of cancer research. However, the accelerated discovery of new cancer genes emerging from large-scale cancer genomics and new chemical entities pouring from the drug discovery pipeline have strained the capacity of traditional germline mouse models to provide crucial insights. This Review introduces new approaches to modelling cancer, with emphasis on a growing collection of non-germline GEMMs (nGEMMs). These offer flexibility, speed and uniformity at reduced costs, thus paving the way for much needed throughput and practical preclinical therapeutic testing models.

AB - Genetically engineered mouse models (GEMMs) of cancer have affected virtually all areas of cancer research. However, the accelerated discovery of new cancer genes emerging from large-scale cancer genomics and new chemical entities pouring from the drug discovery pipeline have strained the capacity of traditional germline mouse models to provide crucial insights. This Review introduces new approaches to modelling cancer, with emphasis on a growing collection of non-germline GEMMs (nGEMMs). These offer flexibility, speed and uniformity at reduced costs, thus paving the way for much needed throughput and practical preclinical therapeutic testing models.

UR - http://www.scopus.com/inward/record.url?scp=77953998205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953998205&partnerID=8YFLogxK

U2 - 10.1038/nrc2877

DO - 10.1038/nrc2877

M3 - Review article

C2 - 20574449

AN - SCOPUS:77953998205

VL - 10

SP - 470

EP - 480

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 7

ER -